A5069011333- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Occupational and environmental lung diseases
- Cancer Genomics and Diagnostics
- Pleural and Pulmonary Diseases
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Ferroptosis and cancer prognosis
- Immune Cell Function and Interaction
- Artificial Intelligence in Healthcare and Education
- Cancer therapeutics and mechanisms
- Immune cells in cancer
- Peptidase Inhibition and Analysis
- Neuroblastoma Research and Treatments
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Tuberculosis Research and Epidemiology
Erasmus University Rotterdam
2020-2024
Erasmus MC
2019-2024
Erasmus MC Cancer Institute
2020-2023
Despite the clinical success of immune checkpoint blockade (ICB), in certain cancer types, most patients with do not respond well. Furthermore, for whom ICB is initially successful, this often short-lived because development resistance to ICB. The mechanisms underlying primary or secondary are incompletely understood. Here, we identified preferential activation and enhanced suppressive capacity regulatory T cells (Treg cells) αPD-L1 therapy-resistant solid tumor-bearing mice. Treg cell...
The clinical value of STK11, KEAP1, and EGFR alterations for guiding immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) remains controversial, as some patients with these proposed resistance biomarkers show durable ICB responses. More specific combinatorial biomarker approaches are urgently needed this disease.
Combined immune checkpoint inhibitor (ICI) treatment targeting PD-1 and CTLA-4 was suggested to yield clinical benefit over chemotherapy in malignant pleural mesothelioma (MPM), whereas aPD-1 monotherapy failed provide phase-III trials. Success of ICI depends on the presence activation tumor-specific T cells. Therefore, we investigated whether T-cell characteristics are underlying efficacy MPM.Comprehensive cell profiling performed screening peripheral blood samples patients treated with...
This study aimed to investigate the cost-effectiveness, budget impact (BI), and of uncertainty future developments concerning whole-genome sequencing (WGS) as a clinical diagnostic test compared with standard care (SoC) in patients locally advanced metastatic non-small cell lung cancer.A total 3 likely scenarios take place within 5 years (according experts) were simulated using previously developed, peer reviewed, published decision model. The concerned "WGS results used for treatment...
We aimed to perform an early cost-effectiveness analysis of using a whole-genome sequencing-based tumor mutation burden (WGS-TMB), instead programmed death-ligand 1 (PD-L1), for immunotherapy treatment selection in patients with non-squamous advanced/metastatic non-small cell lung cancer ineligible targeted therapy, from Dutch healthcare perspective. A decision-model simulating individual metastatic was used evaluate diagnostic strategies select first-line only or the plus chemotherapy...
Abstract Tumour mutational burden (TMB) has emerged as a promising biomarker to predict immune checkpoint inhibitors (ICIs) response in advanced solid cancers. However, harmonisation of TMB reporting by targeted gene panels is lacking, especially metastatic tumour samples. To address this issue, we used data 2841 whole-genome sequenced cancer biopsies perform an silico analysis determined seven (FD1CDx, MSK-IMPACT™, Caris Molecular Intelligence, Tempus xT, Oncomine Mutation Load, NeoTYPE...
Gemcitabine is a frequently used chemotherapeutic agent but its effects on the immune system are incompletely understood. Recently, randomized NVALT19-trial revealed that maintenance gemcitabine after first-line chemotherapy significantly prolonged progression-free survival (PFS) compared to best supportive care (BSC) in malignant mesothelioma. Whether these paralleled by changes circulating cell subsets currently unknown. These analyses could offer improved mechanistic insights into of host...
<div>AbstractPurpose:<p>The clinical value of <i>STK11</i>, <i>KEAP1</i>, and <i>EGFR</i> alterations for guiding immune checkpoint blockade (ICB) therapy in non–small cell lung cancer (NSCLC) remains controversial, as some patients with these proposed resistance biomarkers show durable ICB responses. More specific combinatorial biomarker approaches are urgently needed this disease.</p>Experimental Design:<p>To develop a strategy...
<div>AbstractPurpose:<p>The clinical value of <i>STK11</i>, <i>KEAP1</i>, and <i>EGFR</i> alterations for guiding immune checkpoint blockade (ICB) therapy in non–small cell lung cancer (NSCLC) remains controversial, as some patients with these proposed resistance biomarkers show durable ICB responses. More specific combinatorial biomarker approaches are urgently needed this disease.</p>Experimental Design:<p>To develop a strategy...
<p>The cTMB and outcome of ICB monotherapy in the discovery cohort.</p>
<p>Alterations in STK11, KEAP1, or EGFR and survival of TMB-based subgroups the validation cohort.</p>
<p>STK11/KEAP1/EGFR alterations and survival of TMB-based subgroups in the discovery cohort.</p>
<p>The impact of tumor purity on the WGS-based TMB in discovery cohort.</p>
<p>Alterations in STK11, KEAP1, or EGFR and survival of TMB-based subgroups the validation cohort.</p>
<p>STK11/KEAP1/EGFR alterations and survival of TMB-based subgroups in the discovery cohort.</p>